The aim is to investigate the role of germline mutations in predicting complete remission after chemotherapy in triple-negative breast cancer patients.
Utilized gNGS to detect germline pathogenic and likely pathogenic (P&LP) mutations.
Focused on identifying BRCA and BRCAness mutations.
Analyzed the correlation between mutations and rates of pathological complete response (ypCR).
Findings indicate that specific germline mutations are associated with higher rates of ypCR.
BRCA and BRCAness mutations show a significant predictive value for remission.
The study supports using mutation testing to guide treatment plans.
Abstract
Germline P&LP mutations in TNBC patients can be detected by gNGS. This panel test can identify BRCA and BRCAness mutations that may predict ypCR in TNBC.